Japan Migraine Drugs Market Size, Share, and COVID-19 Impact Analysis, By Treatment (Acute and Preventive), By Route of Administration (Oral, Injectable, and Others), and Japan Migraine Drugs Market Insights, Industry Trend, Forecasts to 2035

Japan Migraine Drugs Market Insights Forecasts to 2035

• The Japan Migraine Drugs Market Size Was Estimated at USD 232.8 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 8.37% from 2025 to 2035
• The Japan Migraine Drugs Market Size is Expected to Reach USD 563.8 Million by 2035

According to a research report published by Spherical Insights & Consulting, The Japan Migraine Drugs Market Size is anticipated to reach USD 563.8 Million by 2035, growing at a CAGR of 8.37% from 2025 to 2035. The Japan migraine drugs market is driven by various factors, including the rising prevalence of migraines, advancements in migraine therapeutics, an aging population, and pharmaceutical investment and regulatory support.

Market Overview

The Japan migraine drugs market focuses on research, development, approval, marketing, and sale of the drugs used to treat and prevent migraines. This market includes a variety of therapeutic alternatives, including treatments for acute conditions and preventive therapies. The Japanese migraine drugs market includes a wide range of therapeutic classes such as CGRP monoclonal antibodies, CGRP small molecule antagonists, acetylcholine inhibitors/neurotoxins, triptans, ditans, ergot alkaloids, and NSAIDs. A significant factor influencing the market is the increasing number of migraine cases, primarily due to lifestyle choices and elevated stress levels in cities like Tokyo and Osaka, which creates the demand for effective medication. Furthermore, the Japanese government's commitment to enhancing healthcare and funding medical research supports the implementation of cutting-edge treatment alternatives. The rising preferences for customized drug formulations are a key trend in this market. The integration of advanced data processing technologies like event stream processing presents a significant opportunity for growth.

Report Coverage

This research report categorizes the market for the Japan migraine drugs market based on various segments and regions, and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan migraine drugs market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan migraine drugs market.

Driving Factors

One of the primary driving factors is the rising incidence of migraine, especially in youth and working professionals, due to stress, unhealthy diets, creating the demand for migraine drugs. The Japan Headache Society has started initiatives to raise awareness among the public and healthcare professionals regarding the symptoms and treatment of migraines, which further creates the demand for diagnosis and effective medications. Japanese pharmaceutical firms are placing greater emphasis on research and development efforts to investigate new therapies that provide enhanced effectiveness and fewer side effects. Japan has one of the largest aging populations, which increases the prevalence of chronic migraine disorders which further expanding the market.

Restraining Factors

The advanced migraine drugs like CGRP inhibitors are expensive, which can be unaffordable for many patients. Several medications have side effects like triptans, which led to CV joint problems, further limiting the market expansion.

Market Segmentation

The Japan migraine drugs market share is classified into treatment and route of administration.

• The preventive segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.  

The Japan migraine drugs market is segmented by treatment into acute and preventive. Among these, the preventive segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to preventative treatment, including drugs and strategies designed to lessen the frequency, severity, and duration of migraine attacks.   

• The injectable segment held the highest share in 2024 and is expected to grow at a substantial CAGR during the forecast period.   

The Japan migraine drugs market is segmented by route of administration into oral, injectable, and others. Among these, the injectable segment held the highest share in 2024 and is expected to grow at a substantial CAGR during the forecast period. This segmental growth is attributed to its quick and effective relief from the migraine symptoms. Additionally, they provide safety and tolerability for acute migraines.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan migraine drugs market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Sumitomo Dainippon Pharma
• Amgen Inc.
• Teva Pharmaceutical
• Otsuka Pharmaceutical Co., Ltd.
• Eli Lilly
• Tsumura Co. Ltd.
• Other

Recent Developments

• In November 2022, Otsuka Pharmaceutical Co., Ltd. launched the Auto-Injector dosage Form for AJOVY Subcutaneous Injection 225mg for Preventive Treatment of Migraine in Japan.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan migraine drugs market based on the below-mentioned segments:

Japan Migraine Drugs Market, By Treatment

• Acute
• Preventive

Japan Migraine Drugs Market, By Route of Administration

• Oral
• Injectable
• Other